All News

Cancer.risk_.jpg

Lymphoma in RA: Disease Activity Matters

d MedPage Today

Among patients with rheumatoid arthritis (RA), the strongest risk factors for the development of lymphoma were disease activity and severity, French researchers found.

In a multivariate analysis, having a high Disease Activity Score in 28 joints (DAS28) at baseline conferred twice the risk for lymphoma, with an odds ratio of 2.09 (95% CI 1.41-3.38), according to Gaetane Nocturne, MD, of Hôpital Bicêtre in Ile-de-France, and colleagues.

Read Article
Covid lung pneumonia corona (keep)

COVID Breakthrough Infections in Rheumatic Patients

d Jack Cush, MD

Analysis of records from the Mass General Brigham healthcare system in the Boston area, shows that breakthrough infections (after receiving SARS-CoV-2 vaccines) in patients with systemic autoimmune rheumatic diseases (SARDs) are not uncommon, and may be severe or fatal.

Read Article
psoriasis,arms,pain

Diagnostic Delay in Half of Psoriatic Arthritis Patients

d Jack Cush, MD

 A Mayo Clinic/ Olmsted County study of psoriatic arthritis (PsA) patients has shown that more than half (55%) of PsA patients had a diagnostic delay of > 2 years, and that this delay has not improved over time.

Read Article
young%20doctors.jpg (keep)

ICYMI: The Greatest Rheumatologist - Part II

d Jack Cush, MD

Wow! I hope you read part I of yesterday's “Greatest Rheumatologist” article.  So many big names and yet, other names and stories that were equally inspirational.



If you read the comments of the part I article you can clearly see several themes emerge.

Read Article
doctors.%20fellows.jpg

ICYMI: The Greatest Rheumatologist - Part I

d Jack Cush, MD

Who is the greatest rheumatologist? What makes for a great rheum? Is it clinical acumen, scientific achievement, educational prowess or years of unrivaled service or mentoring? Rheumatologists are quite opinionated on this subject and very nostalgic about their mentors and leaders. When I’ve posed this question in small groups, it’s plain to see how moved they become when discussing mentors or peers who influenced them. Thus, I posed this question to many of our leaders and mentors: who do you think of as the greatest rheumatologist?

Read Article
UK study shows PreClin RA, Establ #RA 1) have increased bowel permeability; 2) gut permeability worsens w/ activity; 3) gut-permeability markers not affected by treatment; 4) in a RA Mouse model-blocking gut permeability ameliorates arthritis https://t.co/HZNl56cQnn

Links:

Dr. John Cush RheumNow ( View Tweet)

A Mayo Clinic/ Olmsted County study of psoriatic arthritis (PsA) patients has shown that more than half (55%) of PsA patients had a diagnostic delay of > 2 years, and that this delay has not improved over time. #RheumNow https://t.co/6HIImOQ5nc https://t.co/uIjWSYt4JH

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Cush is joined by rheumatology colleagues to discuss impressions and impact of the 9/1/21 FDA Drug Safety Communication to physicians regarding new label changes. #RheumNow https://t.co/F37SCpJnsW https://t.co/uhdOjFo0yP

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has issued 510(k) (medical device) clearance for the marketing of an artificial intelligence algorithm from Radiobotics to diagnose #OA knee - "RBknee™" can identify osteophytes, subchondral sclerosis, joint space narrowing & width https://t.co/cY111NH69w

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: The Greatest Rheumatologist - Part II #RheumNow https://t.co/NBNsmSxxcW https://t.co/n2f01vnugD

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: The Greatest Rheumatologist - Part I Who is the greatest rheumatologist? What makes for a great rheum? Is it clinical acumen, scientific achievement, educational prowess or years of unrivaled service or mentoring? #RheumNow https://t.co/aNKnYtlN4I https://t.co/FBNXuKnbiA

Links:

Dr. John Cush RheumNow ( View Tweet)
Causes of DYSGEUSIA (metallic taste): - Antibiotics (clarithromycin, metronidazole tetracycline), Allopurinol, captopril, Lithium, Methazolamide, Metformin, Lunesta and more... heres a video discussion on this. https://t.co/FphprLh1Sf https://t.co/1wkjQxA9UZ

Links:

Dr. John Cush RheumNow ( View Tweet)

Strept pneumoniae vaccinations are underutilized. A Univ of Pittsburgh project utilized EMR reminders to prompt vax w/ Prevnar/PCV13 & Pneumovax/PPSV23. PPSV23 vax increased 28% to 62% and either PPSV23, PCV13 incr 50% to 77% using EMR https://t.co/DO9WnyBHI1

Links:

Dr. John Cush RheumNow ( View Tweet)

MMWR: COVID-19–hospitalization rates in kids & adolescents rose 5-fold late June–mid-Aug 2021 (w/ rise of Delta variant). Hospitalization rates were 10 times higher among unvaccinated than fully vaccinated adolescents. https://t.co/Qt5lj3Ycxb

Links:

Dr. John Cush RheumNow ( View Tweet)

In case you missed it— Booster Shots for Rheumatology Patients on Immunosuppressive Medications https://t.co/dIzrv3B12u https://t.co/nGIUNcqNTf

Links:

Dr. John Cush RheumNow ( View Tweet)
https://t.co/wM1iRxtHvk The interleukin-6 inhibitor, tocilizumab (TCZ), was studied in a cohort of difficult systemic sclerosis (SSc) and was shown to be effective in refractory joint and skin disease with good long-term retention rates and disease stabilization. https://t.co/UBjpHUlb1l

Links:

Dr. John Cush RheumNow ( View Tweet)
Musculoskeletal sequelae/complications in adults following ICU admission studied by metanalysis of 32 studies. Muscle problems, pain (shoulder pain) predominated. Weakness in 29%, Chronic pain 34%, neuromuscular impairment 51%. https://t.co/FpqDvRDtVq

Links:

Dr. John Cush RheumNow ( View Tweet)

Our latest @MassGenBrigham rheumatology COVID collaboration with @zach_wallace_md #preprint to share quickly. 16 confirmed breakthrough infections in rheumatic patients since vaccine EUAs in US. 15 symptomatic, 6 hospitalized, 2 deaths https://t.co/atixfBcEbn

Links:

Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)

Our @MassGenBrigham @zach_wallace_md rheum COVID paper on breakthrough infections is out now in ARD https://t.co/zOZqF0ecaG

Links:

Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)

Pleased to share our study in A&R investigating rheum evaluation, immunomodulator use, and predictors of rheumatic immune-related adverse events (irAEs) after immune #checkpoint inhibitor use for cancer, led by @BusselKiki @BrighamResearch @DanaFarber https://t.co/6rnSfd08FB

Links:

Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)

×